The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review

Hector Meijide, Savino Sciascia, Giovanni Sanna, Munther A Khamashta, Maria Laura Bertolaccini

Research output: Contribution to journalReview articlepeer-review

71 Citations (Scopus)

Abstract

The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid antibodies (aPL). Diagnostic tests for the detection of antiphospholipid antibodies include laboratory assays that detect anticardiolipin antibodies, lupus anticoagulants, and anti-β(2)-glycoprotein I antibodies. Most studies on aPL have mainly focused on the estimation of the IgG and IgM isotypes, with only a few studies reporting on the pathogenic significance of IgA aPL. In this review we aimed to summarize and analyze the evidence published in the literature on the prevalence and the clinical significance of IgA aPL.
Original languageEnglish
Article numberN/A
Pages (from-to)421-425
Number of pages5
JournalAUTOIMMUNITY REVIEWS
Volume12
Issue number3
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Antibodies, Anticardiolipin
  • Antiphospholipid Syndrome
  • Humans
  • Immunoglobulin A
  • Seroepidemiologic Studies
  • beta 2-Glycoprotein I

Fingerprint

Dive into the research topics of 'The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review'. Together they form a unique fingerprint.

Cite this